Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.19
Views: 270
Rating:

Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA

Dr Yu-Tzu Tai speaks to ecancer at the ASH 2019 meeting in Orlando about updated results from a study evaluating the anti-BCMA bispecific T-cell engager (BiTE) AMG 701 for multiple myeloma.

She reports that AMG 701 can potently induce myeloma cell lysis in sensitive and resistant cells.

Dr Tai also details that they found that AMG 701 significantly induces CD4 and CD8 T cell proliferation and activation.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Read more about the study here

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation